Exelixis and Sanofi-Aventis in $1 billion PI3K cancer deal
This article was originally published in Scrip
Executive Summary
Exelixis could receive up to $1.16 billion from Sanofi-Aventis for licensing the phosphoinositide-3 kinase inhibitor (PI3K) anticancers XL147 and XL765, and a broader collaboration agreement to discover PI3Ks.